PTK2 and schwannoma: Similarly, the non-RTK PTK2/FAK and the serine-threonine kinases GAK, RPS6KA3/RSK2, and MARK3 were also found to be greatly suppressed in brigatinib-treated schwannoma cells (Fig 3).